Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/17746 |
Resumo: | INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. |
id |
USP-19_b533f0828a50411aeccc7388ff2f3d64 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/17746 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly Endothelium^i1^sultrasonograAgedHydroximetilglutaril-CoA reductase inhibitorsC-reactive proteinLipid INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2008-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1774610.1590/S1807-59322008000500004Clinics; Vol. 63 No. 5 (2008); 589-594 Clinics; v. 63 n. 5 (2008); 589-594 Clinics; Vol. 63 Núm. 5 (2008); 589-594 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/17746/19811Crisostomo, Luciola M LSouza, Carlos A MMendes, Carlos M CCoimbra, Silmara RFavarato, DesiderioLuz, Protasio L dainfo:eu-repo/semantics/openAccess2012-05-22T18:30:17Zoai:revistas.usp.br:article/17746Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-22T18:30:17Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
title |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
spellingShingle |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly Crisostomo, Luciola M L Endothelium^i1^sultrasonogra Aged Hydroximetilglutaril-CoA reductase inhibitors C-reactive protein Lipid |
title_short |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
title_full |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
title_fullStr |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
title_full_unstemmed |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
title_sort |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly |
author |
Crisostomo, Luciola M L |
author_facet |
Crisostomo, Luciola M L Souza, Carlos A M Mendes, Carlos M C Coimbra, Silmara R Favarato, Desiderio Luz, Protasio L da |
author_role |
author |
author2 |
Souza, Carlos A M Mendes, Carlos M C Coimbra, Silmara R Favarato, Desiderio Luz, Protasio L da |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Crisostomo, Luciola M L Souza, Carlos A M Mendes, Carlos M C Coimbra, Silmara R Favarato, Desiderio Luz, Protasio L da |
dc.subject.por.fl_str_mv |
Endothelium^i1^sultrasonogra Aged Hydroximetilglutaril-CoA reductase inhibitors C-reactive protein Lipid |
topic |
Endothelium^i1^sultrasonogra Aged Hydroximetilglutaril-CoA reductase inhibitors C-reactive protein Lipid |
description |
INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. |
publishDate |
2008 |
dc.date.none.fl_str_mv |
2008-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17746 10.1590/S1807-59322008000500004 |
url |
https://www.revistas.usp.br/clinics/article/view/17746 |
identifier_str_mv |
10.1590/S1807-59322008000500004 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17746/19811 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 63 No. 5 (2008); 589-594 Clinics; v. 63 n. 5 (2008); 589-594 Clinics; Vol. 63 Núm. 5 (2008); 589-594 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222753467400192 |